New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
07:16 EDTGALEGalena Biopharma enrolls first patient in GALE-301 phase 2 trial
Galena Biopharma announced the first patient has been enrolled in the phase 2 trial for GALE-301. GALE-301 is a folate receptor alpha-derived, peptide-based cancer immunotherapy administered to HLA-A2 positive patients in combination with granulocyte macrophage-colony stimulating factor as an adjuvant treatment to prevent recurrences in high-risk, endometrial and ovarian cancer patients rendered disease-free after completing standard of care therapy. The primary objective of the trial is to measure immune response, with secondary outcomes of recurrence. "With GALE-301 progressing into its Phase 2 trial, we continue to demonstrate progress of our innovative cancer immunotherapy pipeline," said Mark Ahn, president and CEO. Initial results from the Phase 1 trial determined the optimal dose and showed that GALE-301 was well tolerated and evoked a FBP specific immunological response.
News For GALE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2015
07:11 EDTGALEGalena announces collaboration with NCI on Phase 2 trial with NeuVax
Subscribe for More Information
September 28, 2015
07:17 EDTGALEGalena presents 'positive' GALE-301 Phase 2a clinical trial data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use